Cyclacel pharmaceuticals to present preliminary data from the phase 1/2 clinical trial of oral fadraciclib at the 34th eortc-nci-aacr symposium

- preliminary dose escalation data to be presented on novel cdk2/9 inhibitor fadraciclib in patients with solid tumors and lymphoma - - preliminary dose escalation data to be presented on novel cdk2/9 inhibitor fadraciclib in patients with solid tumors and lymphoma -
CYCC Ratings Summary
CYCC Quant Ranking